Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup

10.1080/10428194.2017.1298755

Saved in:

Bibliographic Details
Main Authors:	Heinz Ludwig, Meletios A. Dimopoulos, Philippe Moreau, Wee Joo Chng, Hartmut Goldschmidt, Roman Hajek, Thierry Facon, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Antonio Palumbo, Heidi Gillenwater, Nehal Mohamed, Sanjay Aggarwal, Shibao Feng, Douglas Joshua
Other Authors:	MEDICINE
Format:	Others
Published:	Taylor & Francis 2018
Online Access:	http://scholarbank.nus.edu.sg/handle/10635/141100
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

id	sg-nus-scholar.10635-141100
record_format	dspace
spelling	sg-nus-scholar.10635-1411002024-04-17T09:30:41Z Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup Heinz Ludwig Meletios A. Dimopoulos Philippe Moreau Wee Joo Chng Hartmut Goldschmidt Roman Hajek Thierry Facon Ludek Pour Ruben Niesvizky Albert Oriol Laura Rosinol Aleksandr Suvorov Gianluca Gaidano Tomas Pika Katja Weisel Vesselina Goranova-Marinova Antonio Palumbo Heidi Gillenwater Nehal Mohamed Sanjay Aggarwal Shibao Feng Douglas Joshua MEDICINE 10.1080/10428194.2017.1298755 Leukemia & Lymphoma 58 10 2501-2504 2018-04-26T09:20:00Z 2018-04-26T09:20:00Z 2017-03-17 Others Heinz Ludwig, Meletios A. Dimopoulos, Philippe Moreau, Wee Joo Chng, Hartmut Goldschmidt, Roman Hajek, Thierry Facon, Ludek Pour, Ruben Niesvizky, Albert Oriol, Laura Rosinol, Aleksandr Suvorov, Gianluca Gaidano, Tomas Pika, Katja Weisel, Vesselina Goranova-Marinova, Antonio Palumbo, Heidi Gillenwater, Nehal Mohamed, Sanjay Aggarwal, Shibao Feng, Douglas Joshua (2017-03-17). Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup. Leukemia & Lymphoma 58 (10) : 2501-2504. ScholarBank@NUS Repository. https://doi.org/10.1080/10428194.2017.1298755 1042-8194 http://scholarbank.nus.edu.sg/handle/10635/141100 Taylor & Francis Taylor & Francis
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
description	10.1080/10428194.2017.1298755
author2	MEDICINE
author_facet	MEDICINE Heinz Ludwig Meletios A. Dimopoulos Philippe Moreau Wee Joo Chng Hartmut Goldschmidt Roman Hajek Thierry Facon Ludek Pour Ruben Niesvizky Albert Oriol Laura Rosinol Aleksandr Suvorov Gianluca Gaidano Tomas Pika Katja Weisel Vesselina Goranova-Marinova Antonio Palumbo Heidi Gillenwater Nehal Mohamed Sanjay Aggarwal Shibao Feng Douglas Joshua
format	Others
author	Heinz Ludwig Meletios A. Dimopoulos Philippe Moreau Wee Joo Chng Hartmut Goldschmidt Roman Hajek Thierry Facon Ludek Pour Ruben Niesvizky Albert Oriol Laura Rosinol Aleksandr Suvorov Gianluca Gaidano Tomas Pika Katja Weisel Vesselina Goranova-Marinova Antonio Palumbo Heidi Gillenwater Nehal Mohamed Sanjay Aggarwal Shibao Feng Douglas Joshua
spellingShingle	Heinz Ludwig Meletios A. Dimopoulos Philippe Moreau Wee Joo Chng Hartmut Goldschmidt Roman Hajek Thierry Facon Ludek Pour Ruben Niesvizky Albert Oriol Laura Rosinol Aleksandr Suvorov Gianluca Gaidano Tomas Pika Katja Weisel Vesselina Goranova-Marinova Antonio Palumbo Heidi Gillenwater Nehal Mohamed Sanjay Aggarwal Shibao Feng Douglas Joshua Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup
author_sort	Heinz Ludwig
title	Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup
title_short	Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup
title_full	Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup
title_fullStr	Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup
title_full_unstemmed	Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup
title_sort	carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study endeavor (nct01568866) according to age subgroup
publisher	Taylor & Francis
publishDate	2018
url	http://scholarbank.nus.edu.sg/handle/10635/141100
_version_	1800913207703896064

Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma: Results of the Phase 3 Study ENDEAVOR (NCT01568866) According to Age Subgroup

Similar Items